Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01263847 · ClinicalTrials.gov registry record · Early Phase 1
Galactooligosaccharide (GOS) Supplementation and Calcium Absorption in Girls
A Early Phase 1 study, sponsored by Purdue University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 31
- Enrollment target
NCT01263847: Completed Early Phase 1 study, sponsored by Purdue University.
NCT01263847 is a Early Phase 1 study that has completed, run by Purdue University. The registered enrollment target is 31 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01263847, a Early Phase 1 study, has completed, sponsored by Purdue University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of galactooligosaccharide (GOS) supplementation on calcium absorption and and gut microbe profiles.
Primary Outcome
Calcium absorption will be measured using dual isotope methods. Calcium-44(Ca-44) as calcium chloride will be administered in a yogurt drink provided at breakfast along with a roll, butter, jam and juice. A second isotope, Calcium-43 (Ca-43) as calcium chloride will be administered intravenously, one hour after consumption of breakfast. Urine and blood samples will be collected over a period of 48 hours and levels of Ca-44 and Ca-43 will be measured in urine and blood. Levels of Ca-44 and Ca-43
Interventions
- DIETARY_SUPPLEMENT Galactooligosaccharide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-07 |
| Phase | Early Phase 1 |
What the finished NCT01263847 record still lists
NCT01263847 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 1 intervention - of which Galactooligosaccharide is the first listed.
NCT01263847 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01263847 about?
NCT01263847 is a clinical study titled "Galactooligosaccharide (GOS) Supplementation and Calcium Absorption in Girls". The purpose of this study is to determine the effects of galactooligosaccharide (GOS) supplementation on calcium absorption and and gut microbe profiles.
What is the current status of trial NCT01263847?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 31 participants. The study started on 2009-06. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01263847?
The interventions under investigation include: Galactooligosaccharide (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01263847?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01263847's enrollment target sits among peer trials
31 794th of 2000 higher than 1,194 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia